← All trials
NCT06463847
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2024
- Primary completion
- Oct 30, 2024
- Completion date
- Oct 30, 2026
- First posted
- Jun 18, 2024
- Last posted
- Jul 1, 2024
- Enrollment
- 18
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Wuhan Hamilton Bio-technology Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.